Trump calls for Fed Governor Cook’s resignation over mortgage probe
Mary Beth Fritz, Senior Vice President of Quality & Regulatory at Prestige Consumer Healthcare Inc. (NYSE:PBH), recently executed a series of stock transactions, according to a regulatory filing. On March 3, Fritz sold 6,297 shares of the company’s common stock at an average price of $85.39, totaling approximately $537,700.
In a related transaction on the same day, Fritz exercised stock options to acquire 6,297 shares at a price of $44.33 per share. Following these transactions, Fritz holds 18,835 shares of Prestige Consumer Healthcare. The stock sale was conducted under a prearranged trading plan.
In other recent news, Prestige Brands announced third-quarter earnings and revenue that surpassed expectations, leading to an increase in its full-year 2025 earnings per share (EPS) guidance to approximately $4.50. This upward revision from the previous range of $4.40 to $4.46 was well-received by the market. Following these results, DA Davidson analyst Linda Bolton Weiser raised the price target for Prestige Brands to $104 from $95, maintaining a Buy rating. The analyst cited the company’s strong sales performance, particularly from Summer’s Eve and Clear Eyes products, as a key factor in the price target adjustment.
Additionally, Canaccord Genuity reiterated its Buy rating on Prestige Brands, keeping the price target at $93. The firm highlighted the company’s strategic financial management, including reinvestment in the business and potential mergers and acquisitions (M&A). Prestige Brands’ management emphasized their focus on operational improvements and supplier diversification during a recent discussion with Canaccord analysts. The company maintains a leverage ratio of 2.7 times and robust EBITDA margins in the low-to-mid-30s percentage range.
Looking ahead, Prestige Brands plans to expand its supplier base for Clear Eyes in the second half of fiscal year 2026. DA Davidson expects a 5% year-over-year sales increase for the fourth fiscal quarter of 2025, aided by an easier comparison due to previous supply disruptions. The firm’s updated valuation model reflects increased confidence in the company’s growth potential, with adjustments to the free cash flow growth rate and risk-free rate. Canaccord also noted Prestige Brands’ potential for an accretive M&A transaction within the year, although the company has opportunities to grow its existing portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.